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By linking HIV/AIDS and cancer surveillance data in 12 US regions, breast and reproductive cancer risks with AIDS were compared to
those in the general population. Trends in standardized incidence ratios (SIRs) were assessed by CD4 count, AIDS-relative time, and
calendar time. Standardized incidence ratios were indirectly adjusted for cancer risk factors using data from AIDS cohort participants
and the general population. With AIDS, 313 women developed breast cancer (SIR 0.69, 95% confidence interval (CI) 0.62–0.77), 42
developed ovary cancer (SIR 1.05, 95% CI, 0.75–1.42), and 31 developed uterine corpus cancer (SIR 0.57, 95% CI, 0.39–0.81).
Uterine cancer risk was reduced significantly after age 50 (SIR 0.33). Breast cancer risk was reduced significantly both before (SIR
0.71) and after (SIR 0.66) age 50, and was lower for local or regional (SIR 0.54) than distant (SIR 0.89) disease. Breast cancer risk
varied little by CD4 count (Ptrend¼0.47) or AIDS-relative time (Ptrend¼0.14) or after adjustment for established cancer risk factors.
However, it increased significantly between 1980 and 2002 (Ptrend¼0.003), approaching the risk of the general population. We
conclude that the cancer deficit reflected direct or indirect effects of HIV/AIDS and that anti-HIV therapy reduced these effects.
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Increasing numbers of women have been infected with human
immunodeficiency virus (HIV) and now are living with the
acquired immunodeficiency syndrome (AIDS). The effects of AIDS
on women, particularly in the era of highly active antiretroviral
therapy (HAART), are not well defined. In the era before HAART,
the risks of developing Kaposi sarcoma, anal cancer, and perhaps
lymphoma were lower for women than for men with AIDS (Beral
and Newton, 1998; Goedert, 2000). Other than cervical cancer,
no differences by gender have been reported for the few other
malignancies found in excess among people with AIDS (PWA)
(Goedert et al, 1998; Frisch et al, 2001).
Breast cancer may occur less often in women with AIDS than in
the general population (Goedert et al, 1998; Frisch et al, 2001).
Ovary and uterine corpus cancers have not been associated with
AIDS or other immune deficiencies, but weak associations or
susceptible subgroups may have been overlooked because these
malignancies are relatively rare. No previous study has evaluated
the effects of improving anti-HIV therapies or whether differences
in cancer incidence might merely reflect differences in known risk
factors for cancer.
Using population-based data, we have investigated whether the
risk of breast, ovary, or uterine corpus cancers differ for women
with AIDS, whether breast cancer risk differs with increasing
severity or duration of immune deficiency, or with increasing
availability and efficacy of anti-HIV therapies; also whether
menopause or selected risk factors modify or explain any
associations.
MATERIALS AND METHODS
Detection and definition of cancers
From 2003 through 2005, we linked HIV/AIDS and cancer
registration data (including name, race, sex, dates of birth and
death, and, where available, social security numbers) in 12 regions
of the US to identify cancers arising among PWA (Goedert et al,
1998; Frisch et al, 2001; Borges et al, 2001). Ethical and legal
reviews at all participating HIV/AIDS and cancer registries ensured
that patient confidentiality was maintained.
This study describes the cancer profile of women diagnosed with
AIDS from ages 15 to 91 years, referred to below as the registry
population. Time at risk, expressed as person-years, was calculated
from the start to the end of complete cancer registration in the
particular area, no earlier than 60 months before nor later than 120
months after AIDS onset, and censored at death if less than 120
months after AIDS. Although migration could not be determined,
both the HIV/AIDS and cancer registries used the National Death
Index to ascertain deaths, including those occurring outside the
registration areas. The current study included only invasive
cancers, coded according to the International Classification of
Diseases for Oncology (ICD-O), and analysed by site using the
Surveillance, Epidemiology and End Results program’s ‘Site recode
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ywith KS and mesothelioma’ (Fritz et al, 2000; Ries et al, 2005).
Individual cancer sites (ICD-O C50, C54, and C56.9) were analysed
after excluding tumours at those sites that had unspecified, KS or
NHL histology (codes 8000–8005, 9140, and 9050–9055 or 9590–
9989, respectively).
Measures of relative risk
Detailed statistical methods are provided in the appendix. Briefly,
we used previously described methods to calculate the standar-
dized incidence ratio (SIR), which is the ratio of observed to
expected cancers derived from contemporaneous, racial/ethnic
ancestry-, age-, and registry-specific population-based incidence
rates (Goedert et al, 1998; Frisch et al, 2001). For presentation,
ancestry was grouped as African and other. Expected numbers of
cancer were calculated as the sum of stratum-specific products of
background cancer incidence and person-months at risk among
the PWA and were discounted for periods before AIDS onset to
account for reduced survival following a cancer diagnosis (Breslow
and Day, 1987; Grulich et al, 1999; Frisch et al, 2000; Engels et al,
2003). We calculated 95% confidence intervals (CI) assuming a
Poisson distribution of the observed cancers (Breslow and Day,
1987). For an overall SIR estimate, we used the 15-year period from
60 months before to 120 months after AIDS onset. All subgroup
and trend analyses were preplanned. To estimate cancer risk
before and after menopause, SIRs were calculated by age at cancer
diagnosis, grouped as o50 and X50 years.
We used Poisson modeling and a two-sided score test (Goedert
et al, 1998; Frisch et al, 2001) to evaluate change in SIR across six
AIDS-relative time intervals, as presented. We excluded the AIDS
onset period (6 months before to 3 months after AIDS onset) from
the trend test to reduce the influence of ascertainment bias from
the generally increased diagnostic activity around the time of AIDS
diagnosis. A similar approach was used to evaluate change in SIR
across CD4 lymphocyte count at AIDS onset (limited to years
1990–2002 because CD4 data generally were not available before
1990) and across calendar intervals (limited to 4–27 months after
AIDS onset to focus on an interval when follow-up would be most
complete). In sensitivity analyses (not presented), we found no
difference in the trend in breast cancer SIR with an alternative time
interval (4–60 months after AIDS onset) or calendar intervals
(1980–1986, 1987–1995, 1996–2002). To further assess trends in
SIR, we used Poisson regression to fit linear models for breast
cancer risk across calendar time (1980–2002). Although women
with HIV/AIDS had lower fertility and BMI in the pre-HAART era,
(Lee et al, 2000; Forsyth et al, 2002), the breast cancer deficit with
AIDS was minimally altered by adjustment for these factors.
Indirect adjustment
We used indirect methods to adjust for the different prevalence of
selected cancer risk factors in PWA as compared to the general
population (Steenland and Greenland, 2004). Details are provided
in the Appendix. For the general US population, prevalence data
on age at first live birth, parity, body mass index (BMI), cigarette
smoking, and oral contraceptive use were derived from a weighted
average of women in the 1987 (n¼24898) and 2000 (n¼24503)
National Health Interview Surveys (NHIS) (Centers for Disease
Control and Prevention, 2002). For women with AIDS, prevalence
data on these risk factors were obtained from female participants
with AIDS (henceforth referred to as AIDS patients) in the AIDS
Cancer Cohort Study (n¼483) or the Women’s Interagency HIV
Study (WIHS, n¼693) (Barkan et al, 1998; Nawar et al, 2005).
These two studies included subjects from six of the HIV/AIDS
registry areas (New York City, Los Angeles, San Francisco, Florida,
Massachusetts, and Connecticut), and the demographic character-
istics of the AIDS patients resembled those of our registry
population and of the national female HIV/AIDS population
(Bacon et al, 2005). The majority (59%) of participants in WIHS
were below the Federal poverty level, and 13% did not reside in a
house or apartment (Barkan et al, 1998). We excluded AIDS
patients and NHIS women who had a history of breast cancer.
For breast cancer, we adjusted for the effects of age at first live
birth or nulliparity and BMI with age-specific relative risks (RRs)
(MacMahon et al, 1970; Ballard-Barbash and Swanson, 1996;
Friedenreich, 2001; Althuis et al, 2003). In a sensitivity analysis
that yielded similar results (not presented), we used African
American-specific RRs (Zhu et al, 2005). For uterine corpus
cancer, we adjusted for the joint effects of parity and cigarette
smoking with age-specific RRs (Brinton et al, 1992; Viswanathan
et al, 2005). As a result of sparse data, we separately evaluated the
effect on uterine corpus cancer of BMI (Ballard-Barbash and
Swanson, 1996). We did not adjust for effects of oral contraceptive
use because prevalence of use did not vary materially between the
AIDS patients and the NHIS (data not presented).
RESULTS
In linkages performed during 2003–2005 in 12 regions of the US
with population-based cancer ascertainment, 85268 women were
followed for 665987 person-years, measured from 5 years before to
10 years after an initial AIDS diagnosis. There were 51616 women
of African ancestry (61%), 17705 women of Hispanic ancestry
(21%), 15019 non-Hispanic women of European ancestry (18%),
and 928 women of other or missing ancestry (1%). At AIDS
diagnosis, median age of the women was 36 years (interquartile
range 31–43 years); 90% of the women were age 50 years or
younger.
The incidence of breast and uterine corpus cancers, but not
of ovary cancer, was significantly lower than in the general
population. Specifically, linkage to the cancer registries revealed
313 cases of breast cancer (SIR 0.69; 95% CI, 0.62–0.77), 31 cases
of uterine corpus cancer (SIR 0.57; 95% CI, 0.39–0.81), and 42
cases of ovary cancer (SIR 1.05; 95% CI, 0.75–1.42) among women
with AIDS. Breast cancer SIR was reduced in all groups defined by
age at AIDS onset, including those with AIDS onset before age 35
(SIR 0.69). As shown in Table 1, the SIR for breast and ovary
cancers did not differ by age at cancer diagnosis, a surrogate for
menopause status. In contrast, the uterine corpus cancer SIR
differed by menopause status: 0.86 (95% CI, 0.54–1.32) before age
50 and 0.33 (95% CI, 0.16–0.61) at or after age 50. Standardized
incidence ratio did not vary by racial ancestry for any of the three
cancers (Table 1). Cancer and AIDS records matched exactly on
social security number for 211 (67%) of the breast cancer cases; the
records for the other 102 cases matched on other criteria. Breast
cancer SIR did not vary by availability of social security number
for matching (Table 2). By stage, breast cancer SIR from 4 to 60
months after AIDS onset was 0.49 (95% CI, 0.34–0.68) for locally
invasive cancer, 0.61 (95% CI, 0.42–0.86) for regional dissemina-
tion, and 0.89 (95% CI, 0.40–1.68) for distant metastases (Table 2).
Data for uterine corpus and ovary cancer were too sparse to
evaluate by stage.
We examined trends in SIR with respect to time relative to AIDS
onset and CD4 count, as measures of immune deficiency (Table 2).
Near the time of the initial AIDS-defining condition ( 6t oþ3
months), the SIR was 1.15 (95% CI, 0.87–1.50) for breast cancer,
1.19 (95% CI, 0.48–2.45) for uterine corpus cancer, and 2.90 (95%
CI, 1.54–4.94) for ovary cancer. Excluding this interval of intensive
diagnostic scrutiny, there was no significant trend in the breast
cancer SIR from 60 months before to 120 months after AIDS onset
(Ptrend¼0.14, Table 2). There was no trend with AIDS-relative time
in the SIR for uterine corpus cancer or ovary cancer (Ptrend¼0.72
and 0.94, respectively, data not presented). As with the AIDS-
relative time analyses, CD4 lymphocyte count at AIDS onset was
not significantly associated with SIR for breast cancer
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or ovary cancer (Ptrend¼0.91 and 0.89, respectively, data not
presented).
Calendar time was used as a surrogate for availability of anti-
HIV therapy – little or none pre-1990, single and dual reverse
transcriptase inhibitors in 1990–1995, and HAART after 1995. As
shown in Table 2, for breast cancer occurring 4 to 27 months after
AIDS onset, no cases occurred (vs 4.7 expected) in the cohort with
AIDS onset in 1980–1989, whereas the SIR was 0.38 with AIDS
onset in 1990–1995, and the SIR was 0.83 with AIDS onset in
1996–2002 (Ptrend¼0.002). Excluding the 1980–1989 cohort that
had no cases, the SIR still increased significantly (P¼0.01) from
the 1990–1995 to the 1996–2002 cohort. The significant increase
in breast cancer SIR also was found using single calendar years in
a Poisson regression model (Ptrend¼0.003, Figure 1). Data were
very sparse for years 2000–2002, with only 7.2 breast cancer cases
expected. Comparing the 1990–1995 and the 1996–2002 cohorts,
risk of local stage breast cancer increased from SIR 0.40 (95% CI,
0.22–0.66) to 0.61 (95% CI, 0.38–0.93). Similarly, risk of regional
stage breast cancer risk increased from SIR 0.53 (95% CI, 0.29–
0.88) to 0.77 (95% CI, 0.47–1.19). There was no trend with
calendar time in the SIR for uterine corpus cancer, ovary cancer, or
distant metastatic breast cancer (PtrendX0.5) but data were sparse.
Indirect adjustment for age at first live birth, nulliparity and
BMI had little effect on the breast cancer SIR estimate (SIRadj 0.72
vs 0.69 unadjusted). For uterine corpus cancer overall, there was
little effect with indirect adjustment for parity and smoking (SIRadj
0.59) or for BMI (SIRadj 0.56) compared to the unadjusted estimate
(SIR 0.57). Among postmenopausal women, the SIR for uterine
corpus cancer was modestly attenuated with adjustment for parity
and smoking (SIRadj 0.39) and for BMI (SIRadj 0.37, compared to
the unadjusted SIR 0.33).
DISCUSSION
Women with AIDS had a low incidence of locally invasive and
regionally disseminated breast cancer, but this cancer deficit
attenuated over time to approach the incidence in the general
population. Ovary cancer incidence did not differ with AIDS, but a
uterine corpus cancer deficit was large and statistically significant
among postmenopausal women. Although women with HIV/AIDS
had lower fertility and BMI in the pre-HAART era (Lee et al, 2000;
Forsyth et al, 2002), the breast cancer deficit with AIDS was
minimally altered by adjustment for these factors, and it was
unrelated to CD4 count or AIDS-relative time. A breast cancer
deficit with AIDS has been noted inconsistently in previous, much
smaller studies (Franceschi et al, 1998; Amir et al, 2000; Grulich
et al, 2002; Herida et al, 2003; Hessol et al, 2004).
Cancer risk with HIV/AIDS might reflect differences in
hormonal balance or cycling. In the general population, high
Table 1 Standardized incidence ratio (SIR) of cancer among 85268
women from 60 months before to 120 months after an initial AIDS-
defining event, 1980–2002
a
Cancer cases
SIR
Cancer type subgroup
b Observed Expected (95% CI)
Breast cancer 313 453.3 0.69 (0.62–0.77)
Premenopausal 201 283.6 0.71 (0.61–0.81)
Postmenopausal 112 169.7 0.66 (0.54–0.79)
African ancestry 181 248.1 0.73 (0.63–0.84)
Other ancestry 132 205.2 0.64 (0.54–0.76)
Uterine corpus cancer 31 54.6 0.57 (0.39–0.81)
Premenopausal 21 24.3 0.86 (0.54–1.32)
Postmenopausal 10 30.3 0.33 (0.16–0.61)
African ancestry 13 25.0 0.52 (0.28–0.89)
Other ancestry 18 29.6 0.61 (0.36–0.96)
Ovary cancer 42 40.1 1.05 (0.75–1.42)
Premenopausal 28 25.6 1.09 (0.73–1.58)
Postmenopausal 14 14.5 0.97 (0.53–1.62)
African ancestry 23 18.5 1.25 (0.79–1.87)
Other ancestry 19 21.7 0.88 (0.53–1.37)
aThe 85268 women, aged 15–91, accumulated 665987 person-years, censored at
death and excluding time before and after the population-based cancer registry in the
same region had complete data.
bOther ancestry includes European (including all
Hispanics), other, and missing ancestry. Premenopausal are cancers occurring before
age 50. Postmenopausal are cancers occurring at or after age 50.
Table 2 Standardized incidence ratio (SIR) of breast cancer among
women with AIDS
Breast cancer cases
Observed Expected SIR 95% CI
Matches by social security number
a
High (84%) 111 150.4 0.74 0.61–0.89
Medium (70%) 149 225.6 0.66 0.56–0.78
Low (25%) 53 77.1 0.69 0.51–0.90
Cancer stage
b
Local 37 75.6 0.49 0.34–0.68
Regional 34 55.4 0.61 0.42–0.86
Distant 9 10.2 0.89 0.40–1.68
Missing/unknown 7 8.7 0.81 0.32–1.66
AIDS-relative time (months)
c
 60 to –25 64 119.9 0.53 0.41–0.68
 24 to  7 83 84.1 0.99 0.79–1.22
 6 to +3 56 48.5 1.15
d 0.87–1.50
+4 to +27 47 81.1 0.58 0.43–0.77
+28 to +60 40 70.5 0.57 0.41–0.77
+61 to +120 23 49.2 0.47 0.30–0.70
Ptrend 0.14
CD4 count
e
0–99cellsml
 1 24 44.7 0.54 0.34–0.80
100–199cellsml
 1 31 51.5 0.60 0.41–0.85
X200cellsml
 1 12 17.4 0.69 0.35–1.21
Ptrend 0.47
AIDS onset year
f
1980–1989 0 4.7 0 0–0.78
1990–1995 14 36.7 0.38 0.21–0.64
1996–2002 33 39.6 0.83 0.57–1.17
Ptrend 0.002
aFour registries in ‘high’, three in ‘medium, five in ‘low’. Excludes rural Georgia, which
had no matched breast cancer cases.
bCancer risk by stage during +4 to +60 months
after AIDS onset. One registry with miscoded stage data excluded.
cAIDS-relative
time intervals are: distant pre-AIDS ( 60 to  25), later pre-AIDS ( 24 to  7), at
AIDS onset ( 6 to +3, excluded from trend test), shortly after AIDS onset (+4 to
+27), later after AIDS onset (+28 to +60), and very late after AIDS onset (+61 to
+120).
dPtrend for AIDS-relative time excludes the AIDS onset period ( 6t o+ 3
months).
eObserved and expected cases and SIR presented are for +4 to +60
months by CD4 count at AIDS (within  6 to +3 months of AIDS onset). Results for
breast cancer were similar during +4 to +27 months (Ptrend¼0.63) and +28 to +60
months (Ptrend¼0.58).
fObserved and expected cases and SIR presented are for +4
to +27 months by cohort of AIDS onset: little or no antiretroviral therapy (1980–
1989), availability of single and dual nucleoside reverse transcriptase inhibitors
(1990–1995), and availability of highly active antiretroviral therapy (HAART)
combinations (1996–2002). Breast cancer trend by calendar year of AIDS onset was
similar in two sensitivity analyses. For one, cases occurring in the +4 to +60 post-
AIDS interval were used (Ptrend¼0.01). For the second, using the +4 to +27 post-
AIDS interval, AIDS-onset years were divided as 1980–1986, 1987–1995, and
1996–2002 (Ptrend¼0.006).
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ylevels of serum estrogens and testosterone have been linked with
an increased risk of breast cancer in postmenopausal women (Key
et al, 2002). Although serum levels of sex hormones have not been
convincingly linked to premenopausal breast cancer (Sturgeon
et al, 2004), lower breast cancer risk with increased physical
activity, participation in college athletics, or anorexia nervosa,
which result in infrequent ovulation or shortened luteal phase
cycles (Bernstein et al, 1994; Wyshak and Frisch, 2000; Michels and
Ekbom, 2004), suggests that premenopausal sex hormones also
contribute to breast cancer risk. In women with HIV-related CD4
lymphocyte counts of 200–500cellsml
 1, total estradiol and
testosterone levels were at the low end of the normal range (Miller
et al, 1998). Of note, free testosterone levels were below normal
in one-third of HIV-infected women with normal weight, half of
those with up to 10% of body weight loss, and two-thirds of those
with more severe weight loss, of whom 38% were amenorrheic
(Grinspoon et al, 1997). Generally, however, menstrual cycles of
HIV-infected women are normal or only slightly irregular
(Ellerbrock et al, 1996).
Since the 1980s, HIV/AIDS patients have had marked changes in
body composition that may have affected their endogenous
hormone levels and risk of cancer. In the early 1990s, before
availability of HAART and the current obesity epidemic (Flegal
et al, 2002), one-fifth of HIV-infected women in New York City
reported losing more than 10% of their usual body weight
(Ellerbrock et al, 1996). Then, during the first year on HAART,
BMI increased dramatically, almost entirely with fat (Silva et al,
1998). During the HAART era, HIV-infected women in the US have
tended to be overweight or obese (Shuter et al, 2001; Mulligan et al,
2005). A single BMI value, as we used for adjustment, would not
reflect these substantial and rapid changes. Thus, attenuation of
the breast cancer deficit may still be tied, in part, to increases in
body fat as anti-HIV treatments have been increasingly effective,
available, and used (Herida et al, 2003).
Perhaps the deficit in breast cancer reflects the ability of HIV to
infect, replicate in, and impair proliferation of breast cells (Toniolo
et al, 1995; Southern, 1998). Epithelial cell infection by HIV is
inefficient but occurs through several CD4-independent mechan-
isms (Phillips and Bourinbaiar, 1992). Likewise, HIV can
transiently infect epithelial and stromal cells of the endometrium,
with notable differences in HIV receptor expression and cytotoxic
T-lymphocyte activity by menstrual phase and menopause status
(Howell et al, 1997; Asin et al, 2003; Yeaman et al, 2003). Anti-HIV
medications would likely reduce HIV replication and perhaps
allow cell proliferation, either directly or indirectly (Asin et al,
2003; Bettaccini et al, 2005; Chung et al, 2005). If so, increasing use
and effectiveness of anti-HIV treatments would attenuate the
cancer deficit.
Bias is an important concern for our study. Women with HIV/
AIDS may have been screened infrequently and had conditions
that diverted attention from breast masses or vaginal bleeding
(Preston-Martin et al, 2002). The smaller deficit with distant
metastases (SIR 0.89) than earlier stage breast cancer (SIR 0.54)
implies delayed diagnosis. Screening bias would not readily
account for a breast cancer deficit among young women with
AIDS (SIR 0.69), as routine mammograms are not recommended
before age 40. Screening also is not performed for uterine corpus
cancer. Cancer deficits could be an artefact of cases missed in the
registry match. As many women change names upon marriage or
divorce, sensitivity of the linkage might be lower than the 95%
reported previously (Borges et al, 2001). However, many records
were linked with social security number, and the breast cancer
deficit was unrelated to completeness of records with social
security numbers available for matching. Finally, based on
undetected deaths with central nervous system lymphoma
(unpublished data), we estimate that 15% of the deficit may reflect
migration out of the registration area (Cote et al, 1997).
From 1980 to 2002, women with AIDS had significantly reduced
risk of breast and postmenopausal uterine corpus cancers, but not
of ovary cancer. The cancer deficits were unrelated to immune
deficiency or selected risk factors. We offer two hypotheses for the
breast cancer deficit. First, women with HIV/AIDS had alterations
of reproductive and perhaps other hormones tied to breast cancer
(Rose et al, 2004). Second, HIV infected the breast, impairing
proliferation of malignantly transformed cells. Both mechanisms
would be reduced with effective anti-HIV therapy, resulting in an
increased incidence of breast cancer that approaches that of the
general population.
ACKNOWLEDGEMENTS
This research was supported by the Intramural Research Program
of the National Cancer Institute, National Institutes of Health.
HIV/AIDS and cancer registries in the following regions partici-
pated in the HIV/AIDS Cancer Match Study: the states of Colorado,
Connecticut, Florida, Georgia, Massachusetts, Michigan, and New
Jersey; and the metropolitan areas of Los Angeles, San Diego, and
San Francisco (California), New York City (New York), and Seattle
(Washington). We are grateful for the many staff members at these
registries who collected the data, prepared data files for the
matches, and facilitated the record linkages. We also thank Phil
Virgo (Computer Sciences Corporation, Rockville Maryland) for
performing the record linkages, Norma Kim and Emily Moser (RTI
International, Rockville, Maryland) for study management, and
Dr Robert Biggar for helpful discussions and review of the
manuscript. Data in this manuscript were collected by the
Women’s Interagency HIV Study (WIHS) Collaborative Study
Group with centers (Principal Investigators) located at: New York
City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard
Minkoff); Washington DC Metropolitan Consortium (Mary
Young); The Connie Wofsy Study Consortium of Northern
California (Ruth Greenblatt); Los Angeles County/Southern
California Consortium (Alexandra Levine); Chicago Consortium
(Mardge Cohen); Data Analysis Center (Stephen Gange). The
WIHS is funded by the National Institute of Allergy and Infectious
Diseases with supplemental funding from the National Cancer
Institute, and the National Institute on Drug Abuse (U01-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and
UO1-AI-42590). Funding is also provided by the National Institute
of Child Health and Human Development (UO1-HD-32632) and
the National Center for Research Resources (MO1-RR-00071,
MO1-RR-00079, MO1-RR-00083).
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1980 1985 1990 1995 2000
Year
B
r
e
a
s
t
 
c
a
n
c
e
r
 
S
I
R
Observed
Fitted (P=0.003)
Figure 1 Observed and fitted (linear Poisson regression model)
standardized incidence ratio (SIR) for breast cancer occurring 1–5 years
after AIDS diagnosis (n¼90 observed), by calendar year. A quadratic
Poisson regression model did not fit the data better (P¼0.10) than this
linear model. The number of cancer cases expected in each even-number
year is shown in italics.
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Statistical Appendix
Measures of relative risk
The objective was to compare cancer risk among women with
AIDS, overall and in predefined subgroups, to cancer risk in the
general population. Time at risk for development of cancer started
with onset of complete cancer registration in a PWA’s region,
but no earlier than 60 months before AIDS onset. Time at risk
continued to the end of complete cancer registration in the same
region, but no later than the date of death or 120 months after
AIDS onset if not known dead by that time.
Using methods similar to those of previous studies (Goedert
et al, 1998; Frisch et al, 2001), we calculated the standardized
incidence ratio (SIR) of cancer from 60 months before to 120
months after AIDS onset overall, and also across six AIDS-relative
time intervals, as shown in Table 2. For each time interval, the SIR
was the ratio of observed to expected cancers derived from
contemporaneous population-based incidence rates.
By definition, all persons with cancer before AIDS must have
survived long enough after their cancer diagnosis to develop AIDS.
Failure to take this survival factor into account has a major impact
on the relative risk estimates (Grulich et al, 1999; Engels et al,
2003). Consequently, estimates of the expected cancers, to which
observed cases were compared, must take into account that some
individuals with cancer died or were lost to follow-up before they
developed AIDS. As described previously (Frisch et al, 2000), we
used data from the Surveillance, Epidemiology, and End Results
program 9 (SEER 9) to calculate survival-conditioned cancer
incidence rates covering each month back to 60 months before
AIDS. These calculations were stratified by year of cancer
diagnosis, sex, racial ancestry (African, European, other/un-
known), age (less than 60, 60–69, 70 years and older), and 14
regions, including three sub-regions for Georgia (Atlanta, rural,
and other).
The same stratification was used, except with 5-year age groups
and without year of cancer diagnosis, for cancer incidence rates
after AIDS onset. Expected numbers of cancer were calculated as
the sum of stratum-specific products of background cancer
incidence and person-months at risk among the PWAs (Breslow
and Day, 1987). Racial/ethnic ancestry- and age-specific back-
ground rates were used to calculate expected numbers in all
analyses. Since background cancer rates were not available for
Hispanics, expected cancers in this group were based on cancer
rates for European ancestry. We calculated 95% CI assuming a
Poisson distribution of the observed cancers (Breslow and Day,
1987).
To evaluate the trend in AIDS-relative time, we modeled the
SIR in a Poisson regression model as: ln(Oi/Ei)¼aþbti, in which
Oi and Ei were the observed and expected numbers of cancers,
respectively, in the individual time periods, and ti, was the
midpoint of the time interval, measured from AIDS onset. In this
model, a two-sided score test of b¼0 evaluated whether SIR
changed over time (Goedert et al, 1998; Frisch et al, 2001). To
avoid the influence of ascertainment bias, we disregarded cancers
occurring in the AIDS period in the trend test. Consequently, we
used information from the other periods (two before and the three
after AIDS onset) in trend tests, using midpoints of the person-
years in each of these intervals (t¼ 42,  16, 14, 41, and 77
months, respectively) as values of ti.
To analyse trend by CD4 lymphocyte count, we used CD4 values
closest to AIDS onset, limited to the AIDS period, and also limited
to years 1990–2002 because CD4 data generally were not available
before 1990. Trend in SIR was assessed using the median CD4 count
below 100cellsml
 1 (t¼30cellsml
 1), from 100–199cellsml
 1
(t¼159cellsml
 1), and X200cellsml
 1 (t¼292cellsml
 1).
To analyse trend by calendar time of treatment availability (little
or no antiretroviral therapy (1980–1989), widespread single and
dual nucleoside reverse transcriptase inhibitors (1990–1995), and
HAART combinations (1996–2002)), we used the midpoint of
person-years in each interval (t¼1988.56, 1993.32, and 1997.22,
respectively). We limited the calendar-time analysis to the 4–27
months after AIDS onset to reduce biases associated with changes
in pre-AIDS breast cancer mortality and long term mortality from
all causes after AIDS onset.
Indirect adjustment
The objective was to assess the impact of established cancer risk
factors on the observed SIRs. To do so, we obtained risk-factor
adjusted SIRs with the following formula:
Obaselinejexp
Ebaselinejnonexp
¼
P
s
Os
baselinejexp
P
s
Es
baselinejnonexp
¼
P
s
Os
 
P
r:level¼a
RRa ps
ajexp
     
P
s
Es
 
P
r:level¼a
RRa ps
ajnonexp
     
in which RRa was the relative risk of cancer for the a-th risk factor
value in reference to the baseline; s indexed the age/race strata; and
pa|exp and pa|nonexp were the prevalence of risk factor value ‘a’ in the
AIDS patients (derived from the cohort studies described in the
Methods, above) and the general population (derived from NHIS),
respectively (Steenland and Greenland, 2004).
Data on BMI among women with AIDS were available from
the Women’s Interagency HIV Study and from 333 of the 483
women in the AIDS Cancer Cohort Study. As the data from AIDS
patients were too sparse to cross-classify BMI, age at first live
birth, and age, we assumed that the distribution of BMI was
independent of age at first live birth. We obtained the joint
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ancestry by multiplying the probabilities from the individual
distributions of the risk factors for both AIDS patients and the
NHIS.
For breast cancer analyses, we applied the formula above to
adjust for the effects of parity (five categories: nulliparous, else age
at first live birth o20, 20–24, 25–29, or X30 years) and BMI
(three levels: o23, 23–26.99, or X27kgm
 2 for weightheight
 2).
We divided the AIDS patients and the general population into six
strata (age o35, 35–49, or X50 years; African ancestry or other
ancestry). For age strata o35 and 35–49, we applied breast cancer
RRs derived from pre-menopausal women ages o35 and 35–44,
respectively (Althuis et al, 2003). For age stratum X50, we used
breast cancer RRs from MacMahon (RRs¼2.0, 2.0, 1.6, 1.2, and 1.0
for nulliparous and age at first live birth X30, 25–29, 20–24, and
o2; respectively) and RRs 1.0, 1.1, and 1.2 for BMI o23, 23–26.99,
and X27, respectively, as determined from published studies
(MacMahon et al, 1970; Ballard-Barbash and Swanson, 1996;
Friedenreich, 2001).
For uterine corpus cancer analyses, we adjusted for the joint
effects of parity (parous, nulliparous) and cigarette smoking (no,
yes). We divided the AIDS patients and general population into
four age/race strata (age o50 or X50; African ancestry and other
ancestry). We then applied endometrial cancer RRs of 1.0 and 2.8
for parous and nulliparous women, respectively, for each of the
four age/race strata (Brinton et al, 1992). As reported by others
(Viswanathan et al, 2005), we assumed no effect of smoking in
women aged o50; and we used endometrial cancer RRs of 1.0 and
0.73 for non-smokers and smokers, respectively, for both African-
ancestry and other-ancestry women aged X50. As endometrial
cancer data were sparse, adjustment for BMI was done separately,
using endometrial cancer RRs 1.0, 1.0, and 2.5 for BMI categories
o24, 24–27.99, and X28kgm
 2, respectively, for each of the four
age/race strata (Ballard-Barbash and Swanson, 1996).
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